We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Low Density Lipoprotein Apolipoprotein-B Assay Validated

By LabMedica International staff writers
Posted on 19 Nov 2014
The relationship between apolipoprotein-B (Apo-B) concentration and the risk of developing cardiovascular disease (CVD) is more robust than the relationship between low density lipoprotein cholesterol (LDL-C) concentration and CVD.

It is however unknown if Apo-B or low density lipoprotein (LDL) particle number (LDL-P) has a stronger predictive ability for future CHD and this uncertainty may be due to the inability of current Apo-B assays to separate the contribution of very low-density lipoprotein particles (VLDL-P) from the total Apo-B concentration.

Scientists at the Dartmouth-Hitchcock Medical Center (Lebanon, NH, USA) obtained a total of 300 lithium heparinized patient plasma samples submitted for routine fasting lipid profile. More...
The profile included total cholesterol, high density lipoprotein (HDL), triglycerides and calculated LDL cholesterol and was included for analysis via both the LDL Apo-B assay as well as a Direct LDL assay on a specific immunoassay analyzer.

The LDL Apo-B assay (Maine Standards Company; Windham, ME, USA) for use on the Roche Cobas 6000 analyzer (Indianapolis, IN, USA) is an immunoturbidometric assay employing a polyclonal antiserum against Apo-B. In order to accurately quantify only the Apo-B content on LDL particles, the patient samples are first automatically diluted via the instrument. The collaborating scientists at Maine Standards developed an automated immunoturbidimetric assay for the Cobas 6000 analyzer that specifically quantifies the Apo-B present on the surface of LDL particles.

The LDL Apo-B within-run imprecision was 2.3% at 62 mg/dL and 2.2% at 109 mg/dL. The within-laboratory imprecision was 9.7% at 57 mg/dl and 6.1% at 104 mg/dL. There was no strong linear relationship between the calculated or measured LDL cholesterol concentration and the measured LDL Apo-B concentration. The assay demonstrated laboratory acceptable precision, low limit of quantitation (LoQ) and a wide measurement range. This assay that specifically measures Apo-B on LDL particles demonstrated a positive correlation with LDL-C that is not unlike the relationship between LDL-C and total Apo-B.

The authors concluded that they had verified the relationship between the LDL Apo-B concentration and the LDL-particle assay. This precise and easy to use automated turbidimetric assay for use on the Roche Cobas 6000 analyzer may serve as either a low cost alternative to the high-complexity LDL-particle assay by nuclear magnetic resonance (NMR), or as a screen to identify which patients should have a follow up LDL-particle assessment performed in a reference laboratory. The study was published in the November 2014 issue of the journal Clinical Biochemistry.

Related Links:

Dartmouth-Hitchcock Medical Center 
Maine Standards Company 
Roche 



New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
Candida Glabrata Test
ELIchrom Glabrata
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.